Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Aug 10 · inside the Ichimoku cloud · RSI 50 · MACD below its signal
None of the 29 investors followed here reported a position in 2160.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 2160.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 21, 2026 | Wanstok (Philippe)Director (Executive) | Sale at price 0.35 per share. | 400K | $141.92K |
| Apr 21, 2026 | Wanstok (Philippe)Director (Executive) | Sale at price 0.33 per share. | 400K | $132.28K |
| Apr 20, 2026 | Wanstok (Philippe)Director (Executive) | Sale at price 0.39 per share. | 15.16M | $5.98M |
| Mar 30, 2026 | Zhang (Ruinian)President | — | 71.9K | — |
| Sep 28, 2025 | Zhao (Liang)Director (Executive) | — | 482.3K | — |
| Apr 9, 2025 | Zhang (Ruinian)President | Acquisition at price 0.11 per share. | 90K | $9.54K |
| Mar 27, 2025 | Yan (Luying)Vice President | — | 606.7K | — |
| Mar 27, 2025 | Zhao (Liang)Director (Executive) | — | 303.4K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -33.1 | -10.9 | -23.3 | -11.1 | -30.8 | -35.5 | 3.7 | 15.3 | 0.0 | 0.0 | −78.3% | ||
| 2025 | 13.2 | 18.2 | 1.1 | -2.2 | -4.4 | 3.5 | 57.3 | -3.6 | 0.0 | -11.9 | -0.8 | 0.0 | +73.5% |
| 2024 | -4.3 | -16.1 | -13.1 | -7.1 | -3.8 | -17.8 | -10.8 | -12.2 | 38.5 | -20.0 | -2.8 | -2.9 | −58.0% |
| 2023 | 23.8 | -8.0 | -21.9 | -0.4 | -26.8 | 4.7 | 27.1 | -16.9 | -10.7 | 10.2 | -4.9 | -7.4 | −37.9% |
| 2022 | -16.0 | -8.3 | -4.4 | -2.8 | -15.2 | 33.2 | -22.7 | 17.4 | -22.5 | 8.2 | 5.9 | 3.6 | −32.6% |
| 2021 | -26.6 | 32.7 | 3.0 | -9.1 | -25.5 | -34.3 | -22.0 | -13.0 | -13.4 | -17.7 | −78.4% |
Buy / hold / sell counts
MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of structural heart disease and cardiac rhythm management in China, Europe, the Middle East, Africa, Asia, North America, and internationally. The company offers VitaFlow, a transcatheter aortic valve system; VitaFlow Liberty, a transcatheter aortic valve retrievable and controllable bend delivery system; Alwide, a plus valve balloon dilation catheter; AccuSniper, a double-layer balloon dilation catheter, Angelguide, an advanced pre-shaped ultra-hard guidewire; and AnchorMan, a left atrial appendage occlusion and guidance system. It also provides various active, mitral, and tricuspid valve products; left atrial appendage closure products; surgical accessories; low and high-voltage CRM products; leads and accessories; patient monitoring products; and arrhythmia diagnostic devices. In addition, the company offers clinical solutions, including aortic stenosis and atrial fibrillation-related stroke prevention. Further, it is involved in the manufacturing of raw materials for medical devices treating valvular heart diseases; and properties management. The company was founded in 2009 and is headquartered in Shanghai, China.
No recent headlines.